이 보고서는 세계 망막 의약품 시장을 조사하여 비삼출성 망막 질환에 대한 개요와 함께 향후 5년간의 시장 성장 예측, 주요 향후 동향, 시장 진입 경쟁사 프로필 등을 제공합니다.
This first-edition "2024 Retinal Pharmaceuticals Market Report: GA and Other Nonexudative Diseases" estimates the prevalence of nonexudative retinal diseases and forecasts the treatment market by region for complement inhibitors, gene therapies, and more.
The report examines clinical-stage drug-development programs, reviews the development stages of drug- delivery platforms, and analyzes trends in doctor interest in complement inhibitors in both the United States and Western Europe, as well as patient dosing with complement inhibitors in the United States.
The "2024 Retinal Pharmaceuticals Market Report: GA and Other Nonexudative Diseases" analyzes the market for complement inhibitors, gene therapies, antioxidants, sustained-release devices, and other treatments for geographic atrophy, dry AMD, and additional nonexudative retinal diseases. The report discusses important trends, analyzes key factors for future market success, examines disease prevalence, reviews patient economics and reimbursement, and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 19 competitors are profiled, with discussion of their products, strategic market position, background, and outlook.This report explores a variety of topics intended to provide depth and context to the reader's understanding of market dynamics in this ophthalmic pharmaceutical segment. Our coverage includes: